Q3 2024 13F Holders as of 30 Sep 2024
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
87,692,308
-
Total 13F shares
-
79,491,087
-
Share change
-
+13,216,550
-
Total reported value
-
$663,003,221
-
Put/Call ratio
-
78%
-
Price per share
-
$8.34
-
Number of holders
-
154
-
Value change
-
+$119,235,282
-
Number of buys
-
100
-
Number of sells
-
59
Institutional Holders of Terns Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (TERN) as of Q3 2024
As of 30 Sep 2024,
Terns Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (TERN) was held by
154 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
79,491,087 shares.
The largest 10 holders included
ORBIMED ADVISORS LLC, Vivo Capital, LLC, Soleus Capital Management, L.P., Deep Track Capital, LP, BlackRock, Inc., CITADEL ADVISORS LLC, VR Adviser, LLC, VANGUARD GROUP INC, Schonfeld Strategic Advisors LLC, and Point72 Asset Management, L.P..
This page lists
153
institutional shareholders reporting positions in this security
for the Q3 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.